Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review

Stefano Arcangeli, Marta Scorsetti, Filippo Alongi

Research output: Contribution to journalArticle

Abstract

Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.

Original languageEnglish
Pages (from-to)101-108
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume84
Issue number1
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Hypofractionation
  • Prostate cancer
  • Stereotactic body radiation therapy (SBRT)

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review'. Together they form a unique fingerprint.

  • Cite this